Cargando…

The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer

BACKGROUND: The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sodja, Eva, Rijavec, Matija, Koren, Ana, Sadikov, Aleksander, Korošec, Peter, Cufer, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852967/
https://www.ncbi.nlm.nih.gov/pubmed/27247551
http://dx.doi.org/10.1515/raon-2015-0027
_version_ 1782430018287173632
author Sodja, Eva
Rijavec, Matija
Koren, Ana
Sadikov, Aleksander
Korošec, Peter
Cufer, Tanja
author_facet Sodja, Eva
Rijavec, Matija
Koren, Ana
Sadikov, Aleksander
Korošec, Peter
Cufer, Tanja
author_sort Sodja, Eva
collection PubMed
description BACKGROUND: The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy controls, and to correlate mRNA expression with progression-free survival (PFS) after first-line chemotherapy and overall survival (OS) in advanced SCLC patients. PATIENTS AND METHODS: 50 advanced SCLC patients treated with standard chemotherapy and followed at University Clinic Golnik, Slovenia, between 2009 and 2013 were prospectively included. SOX2, NANOG and OCT4 mRNA expression levels were determined using TaqMan qPCR in whole blood collected prior to chemotherapy. Whole blood of 34 matched healthy individuals with no cancerous disease was also tested. RESULTS: SOX2 mRNA expression was significantly higher in whole blood of SCLC patients compared to healthy controls (p = 0.006). Significant correlation between SOX2 mRNA expression levels and the number of distant metastatic sites was established (p = 0.027). In survival analysis, patients with high SOX2 expression had shorter OS (p = 0.017) and PFS (p = 0.046). In multivariate Cox analysis, an independent value of high SOX2 expression for shorter OS (p = 0.002), but not PFS was confirmed. No significant differences were observed for NANOG or OCT4 expression levels when comparing SCLC patients and healthy controls neither when analysing survival outcomes in SCLC patients. CONCLUSIONS: SOX2 mRNA expression in whole blood might be a promising non-invasive marker for molecular screening of SCLC and important prognostic marker in advanced chemotherapy-treated SCLC patients, altogether indicating important role of cancer stem-like cell (CSC) regulators in cancer spread. Further evaluation of SOX2 as a possible screening/prognostic marker and a therapeutic target of SCLC is warranted.
format Online
Article
Text
id pubmed-4852967
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-48529672016-06-01 The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer Sodja, Eva Rijavec, Matija Koren, Ana Sadikov, Aleksander Korošec, Peter Cufer, Tanja Radiol Oncol Research Article BACKGROUND: The data on expression and clinical impact of cancer stem cell markers SOX2, NANOG and OCT4 in lung cancer is still lacking. The aim of our study was to compare SOX2, NANOG and OCT4 mRNA expression levels in whole blood between advanced small-cell lung cancer (SCLC) patients and healthy controls, and to correlate mRNA expression with progression-free survival (PFS) after first-line chemotherapy and overall survival (OS) in advanced SCLC patients. PATIENTS AND METHODS: 50 advanced SCLC patients treated with standard chemotherapy and followed at University Clinic Golnik, Slovenia, between 2009 and 2013 were prospectively included. SOX2, NANOG and OCT4 mRNA expression levels were determined using TaqMan qPCR in whole blood collected prior to chemotherapy. Whole blood of 34 matched healthy individuals with no cancerous disease was also tested. RESULTS: SOX2 mRNA expression was significantly higher in whole blood of SCLC patients compared to healthy controls (p = 0.006). Significant correlation between SOX2 mRNA expression levels and the number of distant metastatic sites was established (p = 0.027). In survival analysis, patients with high SOX2 expression had shorter OS (p = 0.017) and PFS (p = 0.046). In multivariate Cox analysis, an independent value of high SOX2 expression for shorter OS (p = 0.002), but not PFS was confirmed. No significant differences were observed for NANOG or OCT4 expression levels when comparing SCLC patients and healthy controls neither when analysing survival outcomes in SCLC patients. CONCLUSIONS: SOX2 mRNA expression in whole blood might be a promising non-invasive marker for molecular screening of SCLC and important prognostic marker in advanced chemotherapy-treated SCLC patients, altogether indicating important role of cancer stem-like cell (CSC) regulators in cancer spread. Further evaluation of SOX2 as a possible screening/prognostic marker and a therapeutic target of SCLC is warranted. De Gruyter 2016-04-23 /pmc/articles/PMC4852967/ /pubmed/27247551 http://dx.doi.org/10.1515/raon-2015-0027 Text en © 2016 Radiol Oncol
spellingShingle Research Article
Sodja, Eva
Rijavec, Matija
Koren, Ana
Sadikov, Aleksander
Korošec, Peter
Cufer, Tanja
The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title_full The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title_fullStr The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title_full_unstemmed The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title_short The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
title_sort prognostic value of whole blood sox2, nanog and oct4 mrna expression in advanced small-cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852967/
https://www.ncbi.nlm.nih.gov/pubmed/27247551
http://dx.doi.org/10.1515/raon-2015-0027
work_keys_str_mv AT sodjaeva theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT rijavecmatija theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT korenana theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT sadikovaleksander theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT korosecpeter theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT cufertanja theprognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT sodjaeva prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT rijavecmatija prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT korenana prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT sadikovaleksander prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT korosecpeter prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer
AT cufertanja prognosticvalueofwholebloodsox2nanogandoct4mrnaexpressioninadvancedsmallcelllungcancer